The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques.
Saved in:
| Title: | The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. |
|---|---|
| Authors: | Webb GM; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Molden J; Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, Minnesota, United States of America., Busman-Sahay K; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Abdulhaqq S; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Wu HL; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Weber WC; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Bateman KB; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Reed JS; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Northrup M; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Maier N; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Tanaka S; ImmunityBio, Los Angeles, California, United States of America., Gao L; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Davey B; Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, Minnesota, United States of America., Carpenter BL; Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, Minnesota, United States of America., Axthelm MK; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America., Stanton JJ; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Smedley J; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Greene JM; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Safrit JT; NantKWest, Los Angeles, California, United States of America., Estes JD; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Skinner PJ; Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, Minnesota, United States of America., Sacha JB; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America. |
| Source: | PLoS pathogens [PLoS Pathog] 2020 Mar 12; Vol. 16 (3), pp. e1008339. Date of Electronic Publication: 2020 Mar 12 (Print Publication: 2020). |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
